These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28104509)

  • 1. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
    Villa P; Lassandro AP; Amar ID; Vacca L; Moruzzi MC; Ferrandina G; Terribile D; Masetti R; Scambia G
    Menopause; 2016 Jan; 23(1):33-9. PubMed ID: 26308233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
    Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
    JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study.
    Pedersini R; Cosentini D; Rinaudo L; Zamparini M; Ulivieri FM; di Mauro P; Maffezzoni F; Monteverdi S; Vena W; Laini L; Amoroso V; Simoncini EL; Farina D; Mazziotti G; Berruti A
    Bone Rep; 2023 Jun; 18():101654. PubMed ID: 36700242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy.
    Monteverdi S; Pedersini R; Gallo F; Maffezzoni F; Dalla Volta A; Di Mauro P; Turla A; Vassalli L; Ardine M; Formenti AM; Simoncini EL; Giustina A; Maroldi R; Amoroso V; Berruti A
    JBMR Plus; 2021 Feb; 5(2):e10440. PubMed ID: 33615109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
    Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
    Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters, and bone mineral density.
    Lambrinoudaki I; Flokatoula M; Armeni E; Pliatsika P; Augoulea A; Antoniou A; Alexandrou A; Creatsa M; Panoulis C; Dendrinos S; Papacharalambous X
    Spine J; 2015 Jan; 15(1):86-94. PubMed ID: 25106754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and determinants of radiological vertebral fractures in patients with Klinefelter syndrome.
    Vena W; Pizzocaro A; Indirli R; Amer M; Maffezzoni F; Delbarba A; Leonardi L; Balzarini L; Ulivieri FM; Ferlin A; Mantovani G; Lania AG; Ferrante E; Mazziotti G
    Andrology; 2020 Nov; 8(6):1699-1704. PubMed ID: 32558374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer.
    Lee SJ; Kim KM; Brown JK; Brett A; Roh YH; Kang DR; Park BW; Rhee Y
    Calcif Tissue Int; 2015 Dec; 97(6):551-9. PubMed ID: 26232103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone.
    Sosa M; Jódar E; Saavedra P; Navarro MC; Gómez de Tejada MJ; Martín A; Peña P; Gómez J
    Eur J Intern Med; 2008 Jan; 19(1):51-6. PubMed ID: 18206602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
    Mazziotti G; Pedersini R; Vena W; Cosentini D; Carrone F; Pigni S; Simoncini EL; Torrisi R; Zambelli A; Farina D; Balzarini L; Lania AG; Berruti A
    Calcif Tissue Int; 2022 Nov; 111(5):466-474. PubMed ID: 35902384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.
    Mazziotti G; Doga M; Frara S; Maffezzoni F; Porcelli T; Cerri L; Maroldi R; Giustina A
    Endocrine; 2016 Apr; 52(1):103-10. PubMed ID: 26433736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
    Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
    Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
    J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.
    Bouvard B; Hoppé E; Soulié P; Georgin-Mege M; Jadaud E; Abadie-Lacourtoisie S; Petit Le Manac'h A; Laffitte A; Levasseur R; Audran M; Chappard D; Legrand E
    Ann Oncol; 2012 May; 23(5):1151-1156. PubMed ID: 21903604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
    Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
    Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.